Ms. Lewis is an experienced and versatile professional with over 25 years in the clinical research industry across a variety of therapeutic areas using a range of methodologies and strategies. Her experience includes the design and implementation of phase 3 and 4 studies as well as large-scale global safety and effectiveness registries, clinical trial simulations and digital app experience workshops. She has led numerous qualitative research projects involving patients, caregivers and healthcare professionals. In addition, Ms. Lewis has spearheaded the development of educational materials and communications for patients and physicians, as well as oversight of several large-scale longitudinal survey-based projects. In addition, she has created content for and scripted multiple Investigator Meetings as well as Study Team launch meetings. She has held positions within the healthcare sector, CROs and pharmaceutical industry, as Project Director, Director of Late Phase Research, Director of Health Economics and Outcomes Research, Senior Project Manager, and Senior Clinical Administrator for a research foundation.
Joost Samyn, Belgian, joined Celli Group in April 2021 after 30 years’ experience within the draught beer business. Since January 2022 he is the Regional Business Director WeMeA and in charge of the different branches in Germany, France, and Spain. Together with a great team he’s trying to grow the draught drinks market for beer and also for non-alcoholic drinks and water in the area.
James L. Sherley, M.D., Ph.D. is the founder, President, and CEO of Massachusetts stem cell biotechnology company Asymmetrex, LLC. Asymmetrex develops and markets technologies for advancing stem cell medicine, including the first method achieving specific and accurate certification of the dosage of therapeutic tissue stem cells, called kinetic stem cell (KSC) counting. Asymmetrex’s kinetic stem cell counting platforms are also used to optimize manufacturing of therapeutic stem cells and for evaluations of drug effects on tissue stem cells. Dr. Sherley is a graduate of Harvard College, with a B.A. degree in biology, and the Johns Hopkins University School of Medicine, earning joint M.D. and Ph.D. degrees. Prior to founding Asymmetrex, he held academic research appointments at the Fox Chase Cancer Center, Massachusetts Institute of Technology, and Boston Biomedical Research Institute. Dr. Sherley’s professional awards include Pew Biomedical Research Scholar, Ellison Medical Foundation Senior Scholar in Aging Research, and NIH Director’s Pioneer Award.
Elena Marinova is a co-founder, President and Chair of the BoD of Musala Soft, a 700+ people company that has been implementing for more than 20 years challenging IT projects for top tier multinational enterprises. The company’s portfolio covers some of the most innovative areas like AI, Big Data, IoT, Cloud, and AR/VR and a long list of demanding clients like Commerzbank, KBC Group, Financial Times, IBM, VMware, SAP, Deutsche Telekom, BMW, Volkswagen, Uber and more.
Elena is also spending a lot of her time to work on pushing forward Innovation and Education in the modern society. She has served board member seats at American University of Bulgaria, Bulgarian Association of information Technologies, Bulgarian Association of Software Companies, and is a co-founder of the European Junior Olympiad in Informatics.
As a public speaker Elena has been delivering keynote sessions, participated in and moderated panels in international business and IT conferences and summits in Germany, China, Greece, Macedonia, Bulgaria and US among others. Topics she’s keen on sharing first-hand experience and knowledge include AI, IoT, Innovation, Diversity, Culture & Education, Women in Technology & Leadership.
Maria joined the clinical trials field as a Clinical Trial Assistant for one of the top 10 CROs supporting Clinical Research Associates (CRA) with the management of the trial documentation, focusing on Oncology phases II and III trials. After a Master in Clinical Trial Monitoring and some experience, Maria changed to a CRA role monitoring trials phases I-IV in different therapeutical areas: oncology, respiratory, rare diseases, hematology, etc. Five years later, Maria joined Teckro to help bring technological innovation to clinical sites.
